If you or someone you know has type 2 diabetes and also suffers from kidney issues, there’s a new glimmer of hope on the horizon.
Recent research has shown that a simple blood test could help predict the risk of severe heart and kidney diseases in these individuals.
And the best part? It can even help doctors decide on the best treatment plans. So, what’s all the buzz about? Let’s break it down.
Why is this Important?
To put it in context, diabetes is a major health problem affecting millions of people worldwide. In the United States alone, more than 34 million people have diabetes, and a significant portion of them also have kidney disease.
When you have both diabetes and kidney issues, you’re at a higher risk for heart problems. So, identifying these risks early on can be life-saving.
Usually, doctors use specific indicators in the blood, called “biomarkers,” to figure out how diseases progress or respond to treatment.
Until now, we’ve had some idea that these biomarkers can tell us something about kidney and heart risks in diabetics. But this new research brings a lot more clarity to that picture.
How the Study Worked
The study is part of a larger project called the CREDENCE trial. To keep it simple, CREDENCE was a big experiment that compared the effects of a placebo (a medicine with no active ingredients) and a real medication called canagliflozin.
This drug is often prescribed to treat type 2 diabetes, and it’s different from other diabetes medications because it works directly on the kidneys to help control blood sugar levels.
For this specific study, researchers took blood samples from over 2,600 people who were part of the CREDENCE trial.
They checked these samples for four important markers that might signal heart or kidney problems. The people in the study were also grouped into low, medium, and high-risk categories based on these markers.
What Did They Find?
Some key takeaways from the research were:
Early Warning Signs: High levels of these markers right at the beginning of the study were strongly linked with more severe heart and kidney problems later on.
Treatment Helps: People who took canagliflozin had lower levels of these markers after one and three years. Also, these folks were less likely to be hospitalized for heart failure or other complications.
Most at Risk Benefit the Most: For those who were at the highest risk, the medication seemed to work wonders, reducing the risk of future heart and kidney issues significantly.
The study wasn’t perfect; for example, they didn’t have blood samples from everyone in the larger CREDENCE trial. But the findings are still considered promising.
So, what does this all mean? Well, if doctors can use this simple blood test to figure out who’s at risk, they can start treatments much sooner, potentially saving lives.
This research might even change the guidelines on how diabetes and associated risks are managed.
In a nutshell, this is a big step toward helping people with diabetes and kidney disease live longer, healthier lives.
Further studies will give us even more information, but for now, it’s an exciting development in a field that seriously needs it.
If you care about kidney health, please read studies about how to protect your kidneys from diabetes, and the best and worst diets for diabetic kidney disease you need to know.
For more information about kidney health, please see recent studies that high blood pressure can lead to kidney failure, and results showing these heartburn drugs may cause gradual yet ‘silent’ kidney damage.
The study was published in Circulation.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.